IntrinsicIntrinsic
← All summaries

WEST PHARMACEUTICAL SERVICES INC

WST
Financials & Chart →

Business Summary

West Pharmaceutical Services, Inc. is a leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. The company's customers include leading biologic, generic, pharmaceutical, diagnostic, and medical device companies. Sales outside of the U.S. accounted for 56.7% of consolidated net sales in 2025, and the company anticipates that international operations will continue to represent a significant portion of net sales in the future.

The company competes with several companies, such as Datwyler and Aptar, across its Proprietary Products product lines. In Contract-Manufactured Products, competition varies from smaller regional companies such as SMC Ltd. to large global assembly manufacturers such as Phillips Medisize, and the competitive set also includes CMOs such as Sharp and PCI Pharma Services. The company seeks to differentiate itself by serving as a global supplier of integrated drug containment and delivery systems, leveraging global manufacturing capability and the ability to produce many products at multiple sites.

The company generates revenue through two global business segments: Proprietary Products and Contract-Manufactured Products. Proprietary Products offers elastomers and primary containment, drug delivery devices, integrated systems, and analytical lab services primarily to biologic, generic, and pharmaceutical drug customers. Contract-Manufactured Products focuses on the design, manufacture, and automated assembly of complex devices for pharmaceutical, diagnostic, and medical device customers. The ten largest customers accounted for 47.6% of consolidated net sales in 2025, and one customer individually accounted for more than 10% of consolidated net sales, at 15.8% or $485.9 million .

The Proprietary Products segment offers packaging products including stoppers and seals for injectable packaging systems, syringe and cartridge components, administration systems, and drug containment solutions in the form of vials, syringes, plungers and cartridges. The segment also provides films, coatings, washing, vision inspection and sterilization processes and services, as well as self-injection devices and integrated solutions including analytical lab services, pre-approval primary packaging support, engineering development, regulatory expertise, and after-sales technical support. Proprietary Products net sales were $2,492.1 million in 2025, with gross profit of $1,008.2 million and a gross profit margin of 40.5% .

The Contract-Manufactured Products segment serves as a fully integrated business focused on the design, manufacture, and automated assembly of complex devices, using technologies such as multi-component molding, in-mold labeling, ultrasonic welding, clean room molding, device assembly, and drug handling capabilities. The segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. Contract-Manufactured Products net sales were $582.0 million in 2025, with gross profit of $95.8 million and a gross profit margin of 16.5% .

In December 2025, the company entered into a definitive agreement to sell all manufacturing and supply rights for the SmartDose 3.5mL On-Body Delivery System and associated facilities to AbbVie for approximately $112.5 million , subject to working capital and other adjustments, with the transaction expected to close in mid-2026. During 2025, the company recorded pre-tax restructuring charges of $23.3 million related to two existing restructuring programs, including $18.4 million within other expense (income) related to the January 2025 restructuring plan and $4.9 million within selling, general and administrative expenses for professional services relating to the 2024 plan to optimize the legal structure. The company also recorded charges of $8.4 million related to the SmartDose sale agreement, and cost-method investment impairment charges of $4.5 million within other expense (income). The company repurchased 552,593 shares for $134.0 million under its share repurchase programs during 2025.

Consolidated net sales increased by $180.9 million , or 6.3% , in 2025 to $3,074.1 million , compared to $2,893.2 million in 2024. Consolidated gross profit increased by $105.5 million , or 10.6% , to $1,104.0 million , with gross profit margin improving by 1.4 margin points to 35.9% . Net income was $493.7 million in 2025 compared to $492.7 million in 2024, and diluted EPS was $6.79 versus $6.69 in the prior year. Net cash provided by operating activities was $754.8 million in 2025, compared to $653.4 million in 2024.

Business Outlook

The company continues to pursue strategic initiatives in drug containment components, integrated drug containment systems, novel drug delivery devices, novel therapeutic experiences and administration systems. Research and development efforts remain focused on continued investment in primary injectables in elastomeric components, formulation development and packaging, and drug containment systems, self-injection systems, and drug administration consumables. The company's Synchrony Prefillable Syringe (PFS) System launched in January 2026, and the company increased investment in integrated systems related to this product as well as in engineered plastics and components during 2025.

The company intends to continue its expansion into emerging and/or faster-growing international markets. The company's long-term strategic priorities include focus on talent attraction, retention and engagement; a climate and greenhouse gas reduction strategy that incorporates renewable energy and reduced absolute emissions; developing a more sustainable and responsible supply chain; research and development that begins to incorporate sustainability; and reducing waste to landfill and lowering water intensity in operational processes.

Consolidated gross profit margin increased by 1.4 margin points in 2025 to 35.9% . Proprietary Products gross profit margin increased by 1.9 margin points to 40.5% , driven by increased customer demand, primarily of high value components, higher plant absorption and sales price increases. Contract-Manufactured Products gross profit margin decreased by 1.0 margin points to 16.5% , due primarily to increased production costs, partially offset by sales price increases. Adjusted consolidated operating profit margin was 20.2% in 2025, compared to 19.8% in 2024.

The company must adjust production capacity in accordance with customer demand changes and remains focused on increasing capacity at various facilities through its capital strategy. Capital expenditures were $285.9 million in 2025, compared to $377.0 million in 2024. The company employs a supply chain management strategy involving purchasing from integrated suppliers and uses a critical material planning process within supply chain. As of December 31, 2025, the company employed approximately 10,800 people.

Research and development costs were $74.3 million in 2025, compared to $69.1 million in 2024. Capital expenditures were $285.9 million in 2025. The company repurchased 552,593 shares for $134.0 million under its share repurchase programs during 2025. On February 17, 2026, the Board of Directors authorized a new share repurchase program for the purchase of up to $1.0 billion of the company's common stock. The company paid a quarterly dividend of $0.20 per share in each of the first three quarters of 2024; $0.21 per share in the fourth quarter of 2024 and each of the first three quarters of 2025; and $0.22 per share in the fourth quarter of 2025.

The company faces continued pricing pressure from customers and competitors. If the company is unable to resist or offset the effects of continued pricing pressure through value-added services, improved operating efficiencies and reduced expenditures, or if it has to reduce prices, sales and profitability may suffer. Consolidation in the pharmaceutical and healthcare industries could adversely affect future revenues and operating income, as group purchasing organizations and integrated health delivery networks have placed pricing pressure on suppliers.

The company's business depends to a substantial extent on customers' continued sales and development of products that are delivered by injection, such as GLP-1s. If customers fail to continue to sell, develop and deploy injectable products and opt for products delivered via alternative means, such as oral GLP-1s, or if customers reconfigure their drug products requiring less frequent dosing, the company's sales and profitability may suffer. The company is also exposed to foreign currency fluctuations, as sales outside of the U.S. accounted for 56.7% of consolidated net sales in 2025, and many manufacturing facilities and suppliers are located outside of the U.S.

Risk Factors

The company's sales and profitability are largely dependent on the sale of drug products delivered by injection and the packaging of drug products; if customers fail to continue to develop injectable products and opt for alternative delivery means such as oral GLP-1s, or if drug products are reconfigured to require less frequent dosing, sales and profitability could suffer. The company derives a substantial portion of revenue from a limited number of customers, with the ten largest customers accounting for 47.6% of consolidated net sales in 2025 and one customer individually accounting for 15.8% or $485.9 million ; the loss of or a significant reduction in orders from any of these customers could have a material adverse impact. Disruptions in the supply of key raw materials could adversely impact operations, as many components and raw materials are available only from a single supplier due to quality assurance, sole source availability, or cost effectiveness. The company's rights to key value-added and proprietary products and processes licensed from Daikyo, including Crystal Zenith, FluroTec and B2-coating technologies, are pursuant to agreements that expire in 2027 ; if these agreements are terminated early or not renewed, the company's business could be adversely impacted. The company is subject to a securities class action filed on May 5, 2025, alleging violations of securities laws in connection with public statements and certain officers' stock transactions, seeking unspecified damages, costs and expenses.

Management Priorities

Management's discussion emphasizes the company's position as a leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. The top priority is delivering quality products that meet exact product specifications and quality standards. Management highlights that consolidated net sales increased by 6.3% in 2025 to $3,074.1 million , including a favorable foreign currency translation impact of $56.4 million . Adjusted consolidated operating profit was $622.4 million with an adjusted operating profit margin of 20.2% . The strategic priorities emphasized include continued investment in primary injectables in elastomeric components, formulation development and packaging, drug containment systems, self-injection systems, and drug administration consumables, as well as the launch of the Synchrony Prefillable Syringe (PFS) System in January 2026. Management also notes the company's commitment to sustainability, including a climate and greenhouse gas reduction strategy, and the expansion of philanthropic scope to include more sustainability related initiatives.

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — International
  2. [2] Item 1, Business — Marketing
  3. [3] Item 1, Business — Marketing
  4. [4] Item 1, Business — Marketing
  5. [5] Item 7, MD&A — Results of Operations, Net Sales
  6. [6] Item 7, MD&A — Results of Operations, Gross Profit
  7. [7] Item 7, MD&A — Results of Operations, Gross Profit
  8. [8] Item 7, MD&A — Results of Operations, Net Sales
  9. [9] Item 7, MD&A — Results of Operations, Gross Profit
  10. [10] Item 7, MD&A — Results of Operations, Gross Profit
  11. [11] Item 8, Note 1 — Basis of Presentation and Summary of Significant Accounting Policies
  12. [12] Item 7, MD&A — Financial Performance Summary
  13. [13] Item 7, MD&A — Financial Performance Summary
  14. [14] Item 7, MD&A — Financial Performance Summary
  15. [15] Item 7, MD&A — Financial Performance Summary
  16. [16] Item 7, MD&A — Financial Performance Summary
  17. [17] Item 8, Note 4 — Net Income Per Share
  18. [18] Item 8, Note 4 — Net Income Per Share
  19. [19] Item 7, MD&A — Results of Operations, Net Sales
  20. [20] Item 7, MD&A — Results of Operations, Net Sales
  21. [21] Item 8, Consolidated Statements of Income
  22. [22] Item 8, Consolidated Statements of Income
  23. [23] Item 7, MD&A — Results of Operations, Gross Profit
  24. [24] Item 7, MD&A — Results of Operations, Gross Profit
  25. [25] Item 8, Consolidated Statements of Income
  26. [26] Item 7, MD&A — Results of Operations, Gross Profit
  27. [27] Item 8, Consolidated Statements of Income
  28. [28] Item 8, Consolidated Statements of Income
  29. [29] Item 8, Consolidated Statements of Income
  30. [30] Item 8, Consolidated Statements of Income
  31. [31] Item 8, Consolidated Statements of Cash Flows
  32. [32] Item 8, Consolidated Statements of Cash Flows
  33. [33] Item 7, MD&A — Results of Operations, Gross Profit
  34. [34] Item 7, MD&A — Results of Operations, Gross Profit
  35. [35] Item 7, MD&A — Results of Operations, Gross Profit
  36. [36] Item 7, MD&A — Results of Operations, Operating Profit
  37. [37] Item 7, MD&A — Results of Operations, Operating Profit
  38. [38] Item 8, Consolidated Statements of Cash Flows
  39. [39] Item 8, Consolidated Statements of Cash Flows
  40. [40] Item 1, Business — Human Capital Management
  41. [41] Item 7, MD&A — Results of Operations, Research and Development Costs
  42. [42] Item 7, MD&A — Results of Operations, Research and Development Costs
  43. [43] Item 8, Consolidated Statements of Cash Flows
  44. [44] Item 8, Note 4 — Net Income Per Share
  45. [45] Item 8, Note 4 — Net Income Per Share
  46. [46] Item 8, Note 4 — Net Income Per Share
  47. [47] Item 5, Market for Registrant's Common Equity — Dividends
  48. [48] Item 5, Market for Registrant's Common Equity — Dividends
  49. [49] Item 5, Market for Registrant's Common Equity — Dividends
  50. [50] Item 1, Business — International
  51. [51] Item 1, Business — Marketing
  52. [52] Item 1, Business — Marketing
  53. [53] Item 1, Business — Marketing
  54. [54] Item 1A, Risk Factors — Business and Operational Risks
  55. [55] Item 7, MD&A — Results of Operations, Net Sales
  56. [56] Item 8, Consolidated Statements of Income
  57. [57] Item 7, MD&A — Results of Operations, Net Sales
  58. [58] Item 7, MD&A — Financial Performance Summary
  59. [59] Item 7, MD&A — Results of Operations, Operating Profit
  60. [60] Item 8, Consolidated Statements of Income
  61. [61] Item 8, Consolidated Statements of Income
  62. [62] Item 8, Consolidated Statements of Income
  63. [63] Item 8, Consolidated Statements of Income
  64. [64] Item 8, Consolidated Statements of Income
  65. [65] Item 8, Consolidated Statements of Income
  66. [66] Item 8, Consolidated Statements of Income
  67. [67] Item 8, Consolidated Statements of Income
  68. [68] Item 7, MD&A — Results of Operations, Operating Profit
  69. [69] Item 7, MD&A — Results of Operations, Operating Profit
  70. [70] Item 7, MD&A — Financial Performance Summary
  71. [71] Item 7, MD&A — Results of Operations, Operating Profit
  72. [72] Item 8, Consolidated Statements of Cash Flows
  73. [73] Item 8, Consolidated Statements of Cash Flows
  74. [74] Item 8, Consolidated Balance Sheets
  75. [75] Item 8, Consolidated Balance Sheets
  76. [76] Item 8, Consolidated Balance Sheets
  77. [77] Item 8, Consolidated Balance Sheets
  78. [78] Item 7, MD&A — Financial Performance Summary
  79. [79] Item 7, MD&A — Financial Performance Summary
  80. [80] Item 7, MD&A — Financial Performance Summary
  81. [81] Item 7, MD&A — Results of Operations, Net Sales
  82. [82] Item 7, MD&A — Results of Operations, Operating Profit
  83. [83] Item 7, MD&A — Results of Operations, Net Sales
  84. [84] Item 7, MD&A — Results of Operations, Operating Profit

Analysis on 6/8/2026